Clinical implication of MicroRNA for lung cancer

Cancer Biotherapy and Radiopharmaceuticals

Volumn 28, Issue 4, 2013, Pages 261-267

  Wang, Yang ^a,b   Zhang, Xinwei ^a,b   Liu, Liang ^a,b   Li, Hui ^a,b   Yu, Jinpu ^a,b   Wang, Changli ^a,b   Ren, Xiubao ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

Author keywords

Biomarker; Diagnosis; Lung cancer; miRNA; Prognosis

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; HISTONE DEACETYLASE 1; MICRORNA; MICRORNA 101; MICRORNA 126; MICRORNA 205; MICRORNA 21; MICRORNA 210; MICRORNA 486 5P; MUCIN 1; PROTEIN P53; RNA POLYMERASE II; UNCLASSIFIED DRUG; TUMOR MARKER;

3' UNTRANSLATED REGION; ANGIOGENESIS; APOPTOSIS; BASE PAIRING; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE; CELL INVASION; CELL PROLIFERATION; DNA METHYLATION; DRUG TARGETING; GENE AMPLIFICATION; GENE OVEREXPRESSION; HISTONE MODIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG SQUAMOUS CELL CARCINOMA; METASTASIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; PROGNOSIS; SECONDARY;

CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICRORNAS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84877851616     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2012.1401     Document Type: Review

References (59)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69.
2. Dominioni L, Imperatori A, Rovera F, et al. Stage I nonsmall cell lung carcinoma: Analysis of survival and implications for screening. Cancer 2000;89:2334.
3. Bartel DP. MicroRNAs: Target recognition and regulatory functions. Cell 2009;136:215.
4. Takamizawa J, Konishi H, Yanagisawa K. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004;64:3753.
5. Wang R, Wang ZX, Yang JS, et al. MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene 2011; 30: 2644.
6. Lu Y, Thomson JM, Wong HY, et al. Transgenic overexpression of the microRNA miR-17-92 cluster promotes proliferation and inhibits differentiation of lung epithelial progenitor cells. Dev Biol 2007;310:442.
7. Ivanovska I, Ball AS, Diaz RL, et al. MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol 2008;28:2167.
8. Chen LT, Xu SD, Xu H, et al. MicroRNA-378 is associated with non-small cell lung cancer brain metastasis by promoting cell migration, invasion and tumor angiogenesis. Med Oncol 2012;29:1673.
9. Wang X, Ling C, Bai Y, et al. MicroRNA-206 is associated with invasion and metastasis of lung cancer. Anat Rec (Hoboken) 2011;294:88.
10. Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004;23:4051.
11. Cai X, Hagedorn CH, Cullen BR. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA 2004;10:1957.
12. Denli AM, Tops BB, Plasterk RH, et al. Processing of primary microRNAs by the microprocessor complex. Nature 2004; 432:231.
13. Gregory RI, Yan KP, Amuthan G, et al. The microprocessor complex mediates the genesis of microRNAs. Nature 2004; 432:235.
14. Landthaler M, Yalcin A, Tuschl T. The human DiGeorge syndrome critical region gene 8 and Its D. melanogaster homolog are required for miRNA biogenesis. Curr Biol 2004;14:2162.
15. Lee Y, Ahn C, Han J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003;425:415.
16. Hutvagner G, McLachlan J, Pasquinelli AE, et al. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science 2001;293:834.
17. Pillai RS, Bhattacharyya SN, Filipowicz W. Repression of protein synthesis by miRNAs: How many mechanisms? Trends Cell Biol 2007;17:118.
18. Wang S, Olson EN. AngiomiRs - key regulators of angiogenesis. Curr Opin Genet Dev 2009;19:205.
19. Kumarswamy R, Mudduluru G, Ceppi P, et al. MicroRNA-30a inhibits epithelial-To-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer. Int J Cancer 2012;130:2044.
20. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004;22:2954.
21. Zhang JG, Wang JJ, Zhao F, et al. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta 2010;411:846.
22. Calin GA, Sevignani C, Dumitru CD, et al. Human micro-RNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004;101:2999.
23. Yang L, Li Y, Cheng M, et al. A functional polymorphism at microRNA-629-binding site in the 3¢-untranslated region of NBS1 gene confers an increased risk of lung cancer in Southern and Eastern Chinese population. Carcinogenesis 2012; 33:338.
24. Campayo M, Navarro A, Vinolas N, et al. A dual role for KRT81: A miR-SNP associated with recurrence in non-smallcell lung cancer and a novel marker of squamous cell lung carcinoma. PLoS One 2011;6:e22509.
25. Vinci S, Gelmini S, PratesiN, et al.Genetic variants inmiR-146a, miR-149, miR-196a2, miR-499 and their influence on relative expression in lung cancers. Clin Chem LabMed 2011;49:2073.
26. Tian T, Shu Y, Chen J, et al. A functional genetic variant in microRNA-196a2 is associated with increased susceptibility of lung cancer in Chinese. Cancer Epidemiol Biomarkers Prev 2009;18:1183.
27. Hu Z, Chen J, Tian T, et al. Genetic variants of miRNA sequences and non-small cell lung cancer survival. J Clin Invest 2008;118:2600.
28. Watanabe K, Emoto N, Hamano E, et al. Genome structurebased screening identified epigenetically silenced microRNA associated with invasiveness in non-small-cell lung cancer. Int J Cancer 2012;130:2580.
29. Fabbri M, Garzon R, Cimmino A, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A 2007;104:15805.
30. Jeon HS, Lee SY, Lee EJ, et al. Combining microRNA-449a/b with a HDAC inhibitor has a synergistic effect on growth arrest in lung cancer. Lung Cancer 2012;76:171.
31. Zhang JG, Guo JF, Liu DL, et al. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2. J Thorac Oncol 2011;6:671.
32. Luo L, Zhang T, Liu H, et al. MiR-101 and Mcl-1 in nonsmall-cell lung cancer: Expression profile and clinical significance. Med Oncol 2012;29:1681.
33. Boeri M, Verri C, Conte D, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A 2011;108:3713.
34. Chen X, Hu Z, Wang W, et al. Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int J Cancer 2012;130:1620.
35. Xie Y, Todd NW, Liu Z, et al. Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer 2010;67:170.
36. Keller A, Leidinger P, Gislefoss R, et al. Stable serum miRNA profiles as potential tool for non-invasive lung cancer diagnosis. RNA Biol 2011;8:506.
37. Bianchi F, Nicassio F, Marzi M, et al. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med 2011;3:495.
38. Wang ZX, Bian HB, Wang JR, et al. Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer. J Surg Oncol 2011;104:847.
39. Wei J, Gao W, Zhu CJ, et al. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer 2011;30:407.
40. Lin Q, Mao W, Shu Y, et al. A cluster of specified micro-RNAs in peripheral blood as biomarkers for metastatic nonsmall-cell lung cancer by stem-loop RT-PCR. J Cancer Res Clin Oncol 2012;138:85.
41. Lu Y, Govindan R, Wang L, et al. MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer. Carcinogenesis 2012;33:1046.
42. Bishop JA, Benjamin H, Cholakh H, et al. Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res 2010;16:610.
43. Lebanony D, Benjamin H, Gilad S, et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol 2009;27:2030.
44. Shen J, Todd NW, Zhang H, et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest 2011;91:579.
45. Jiang L, Huang Q, Zhang S, et al. Hsa-miR-125a-3p and hsamiR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells. BMC Cancer 2010;10:318.
46. Bracken CP, Gregory PA, Kolesnikoff N, et al. A doublenegative feedback loop between ZEB1-SIP1 and the micro-RNA-200 family regulates epithelial-mesenchymal transition. Cancer Res 2008;68:7846.
47. Qi J, Rice SJ, Salzberg AC, et al. MiR-365 regulates lung cancer and developmental gene thyroid transcription factor 1. Cell Cycle 2012;11:177.
48. Kim NH, Kim HS, Li XY, et al. A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. J Cell Biol 2011;195:417.
49. Arora S, Ranade AR, Tran NL, et al. MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration. Int J Cancer 2011;129:2621.
50. Gao W, Shen H, Liu L, et al. MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. J Cancer Res Clin Oncol 2011; 137:557.
51. Donnem T, Lonvik K, Eklo K, et al. Independent and tissuespecific prognostic impact of miR-126 in nonsmall cell lung cancer: Coexpression with vascular endothelial growth factor-A predicts poor survival. Cancer 2011;117:3193.
52. Patnaik SK, Kannisto E, Mallick R, et al. Overexpression of the lung cancer-prognostic miR-146b microRNAs has a minimal and negative effect on the malignant phenotype of A549 lung cancer cells. PLoS One 2011;6:e22379
53. Bian HB, Pan X, Yang JS, et al. Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). J Exp Clin Cancer Res 2011;30:20
54. Zhang S, Zhang C, Li Y, et al. miR-98 regulates cisplatininduced A549 cell death by inhibiting TP53 pathway. Biomed Pharmacother 2011;65:436.
55. Galluzzi L, Morselli E, Vitale I, et al. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 2010;70:1793.
56. Catuogno S, Cerchia L, Romano G, et al. miR-34c may protect lung cancer cells from paclitaxel-induced apoptosis. Oncogene 2013;32:341.
57. Kasinski AL, Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic: Progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 2011;11:849.
58. Wiggins JF, Ruffino L, Kelnar K, et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 2010;70:5923.
59. Wang PY, Li YJ, Zhang S, et al. Regulating A549 cells growth by ASO inhibiting miRNA expression. Mol Cell Biochem 2010;339:163.